Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

Not Applicable

Recruiting

• Conditions: Dry Eye Syndromes; Dry Eye Disease; Meibomian Gland Dysfunction; Cataract Senile
• Interventions: Device: Systane iLux Treatment

• Registration Number: NCT06483750
• Lead Sponsor: George Washington University

Brief Summary

This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.

Detailed Description

Eligible patients to be recruited will have scheduled upcoming senile cataract surgery. Enrolled patients in the active arm (n=25) will receive pre-operative Systane iLux treatment two weeks prior to surgery at the baseline visit. Patients in the control arm will receive no Systane iLux treatment at the baseline visit two weeks prior to cataract surgery. Patients will be assessed on baseline metrics for dry eye disease stemming and meibomian gland dysfunction (MGD) at the baseline visit two weeks prior to cataract surgery. These metrics include tear break up time (TBUT), standard patient evaluation of eye dryness questionnaire (SPEED), ocular surface and surface disease index (OSDI) surveys, and lipid layer thickness (LLT). At the follow up visit four weeks after cataract surgery, these same metrics will be assessed again for any significant changes.

Study Timeline

• Study Start: 2024-06-03
• Study First Submitted: 2024-06-26
• Study First Submitted QC: 2024-06-26
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-02
• Study First Posted: 2024-07-03
• Last Update Posted: 2024-07-03
• Primary Completion: 2024-09-01
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Age greater than 18 at the time of informed consent
• Must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions
• Upcoming scheduled senile cataract surgery

Exclusion Criteria

• Eyelid abnormalities
• Patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months
• Ocular surgery within the last 6 months
• Occlusion therapy with lacrimal or punctum plugs within the last 3 months
• Patients with an ocular surface abnormality that may compromise corneal integrity
• Patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months)
• Patients with cicatricial lid margin disease
• patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia
• Patients with permanent makeup or tattoos on their eyelids.
• Previous application/administration of Systane iLux or LipiFlow treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Systane iLux Treatment	Systane iLux Treatment	Systane iLux administration at baseline visit two weeks prior to cataract surgery.

Primary Outcome Measures

Name	Time	Method
Changed in Lipid Layer Thickness (LLT) measurement from baseline visit	6 weeks	To assess improvement in tear film lipid layer by imaging through LipiView II. Thin lipid layer thickness (\<60 nm) indicates a tear film instability and therefore an increased evaporation rate, high osmolarity, and dry eye symptoms. In contrast, a thicker lipid layer thickness (\<120 nm) indicates a more stable tear film stability

Secondary Outcome Measures

Name	Time	Method
Change in ocular surface and disease index (OSDI) score questionnaire from baseline visit	6 weeks	The OSDI survey provides a score from 0 to 100 with a higher score indicating a more severe symptoms of dry eye disease. A normal score fro patients without dry eye would be 12 or below, while a score of 13 to 22 indicates mild disease, 23 to 32 indicates moderate disease, and patients with a score above 33 are characterized as having severe eye disease. Change = (Follow up visit score - Baseline visit score)
Change in standard patient evaluation of eye dryness questionnaire (SPEED) questionnaire from baseline visit	6 weeks	To assess the improvement of dry eye symptoms by SPEED questionnaire. 0 score is the minimum (no dry eye symptom); 64 is the maximum score (most symptomatic). Change = (Follow up visit score - Baseline score)
Mean change from baseline of Fluorescein Tear Break-Up Time (TBUT) from baseline visit	6 weeks	The shorter the TBUT, the lower the tear film stability. Lower tear film stability is associated with dry eye. Change = (Follow up visit value - baseline visit value). shorter the TBUT, the lower the tear film stability. Lower tear film stability is associated with dry eye. Change = (Follow up visit value - baseline visit value).
Change from baseline in Meibomian Gland Score (MGS)	6 weeks	Meibomian glands on the eyelids assessed by the examiner using a Meibomian Gland Evaluator (MGE) and a slit lamp microscope. An MGE instrument applies a standardized force simulating the pressure of a deliberate blink allowing eye care professionals to observe meibomian gland functionality through a slit lamp. 5 glands in 3 zones (nasal, medial, temporal) evaluated for each eye and scored from 0 to 3, with a resultant overall score (MGS) of 0 to 45 for each eye. Scoring as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A higher change from baseline score indicates an improvement in meibomian gland function

Trial Locations

Locations (1)

George Washington University; 🇺🇸 Washington, District of Columbia, United States